ReviewHormones (Athens, Greece)2025
Glucose dynamics in glycogen storage disease type IXa with novel PHKA2 variants: insights from our experience and a comprehensive review of the disease spectrum.
Review in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes.Endocrinology, diabetes & metabolism · 2026Pooled it
- RNA sequencing resolves a novel noncanonical splice-region variant inTranslational pediatrics · 2026Article
- Dietary and Therapeutic Management of Glycogen Storage Disease Type IX: Analysis of a Systematic Review.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycogen storage disease type IXa (GSD IXa), caused by phosphorylase kinase mutations, primarily PHKA2, presents variably from mild hepatomegaly to severe liver dysfunction or isolated ketotic hypoglycemia. Its phenotypic overlap with other metabolic disorders complicates diagnosis, requiring genetic confirmation.
methodsWe retrospectively analyzed clinical, biochemical, genetic, and radiological data from patients affected by GSD IXa diagnosed at our regional metabolic disease center in Bologna (Emilia-Romagna, Italy) over recent decades and we reviewed the relevant scientific literature on the pathology.
resultsWe report three patients with recurrent symptomatic ketotic hypoglycemia affected by PHKA2 variants of uncertain significance (VUS) and review the literature concerning GSD IXa.
conclusionGSD IXa should be considered in the differential diagnosis even when persistent ketotic hypoglycemia is the sole presenting feature, underscoring the critical importance of clinical suspicion in such cases. Improved genetic testing has refined diagnosis, even in milder cases without hepatomegaly, while dietary management with uncooked cornstarch (CS) and extended-release cornstarch (ER-CS) effectively prevents complications and maintains good glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.